OpenAI has introduced GPT-Rosalind, a frontier reasoning model engineered to support research across biology, drug discovery, and translational medicine. Named after Rosalind Franklin—whose research was pivotal in revealing the structure of DNA—the model aims to reduce the long timelines associated with pharmaceutical development. In the US, it typically takes 10 to 15 years for a new drug to move from initial target discovery to regulatory approval. OpenAI suggests that gains made during the earliest discovery stages, such as better target selection and stronger biological hypotheses, compound to create higher-quality experiments downstream.
Advancing drug discovery with GPT-Rosalind reasoning
The GPT-Rosalind series is optimized for complex scientific workflows, combining improved tool use with a deeper understanding of chemistry, protein engineering, and genomics. Unlike general-purpose models, this system is designed to reason over molecules, proteins, genes, and disease-relevant biology. During performance evaluations, the model demonstrated improved ability to interpret chemical reaction mechanisms and analyze the effects of mutations on protein structures.
In industry benchmarks, the model consistently outperformed previous iterations. On BixBench—a benchmark designed for bioinformatics and data analysis—GPT-Rosalind achieved a score of 0.761, surpassing models like Gemini 3.1 Pro and Grok 4.2. Furthermore, on LABBench2, the model outperformed GPT-5.4 on six out of 11 tasks, including literature retrieval, sequence manipulation, and protocol design. These reasoning capabilities allow researchers to surface connections that might otherwise be missed across large volumes of fragmented data.
Integrating modular tools into scientific workflows
To assist researchers in navigating multi-step questions, OpenAI has released a life sciences research plugin for Codex on GitHub. This plugin acts as an orchestration layer, providing modular skills that span human genetics, functional genomics, and clinical evidence. It includes a research router entry point that can synthesize evidence-backed answers and utilize subagents for parallel work when data lanes are independent.
Leading organizations such as Amgen, Moderna, and the Allen Institute are already applying GPT-Rosalind to their research pipelines. By transforming clinical lab workflows with AI and automation, these institutions can move more rapidly from raw experimental data to grounded discovery decisions. The model's ability to select the right computational tools and interpret experimental outputs suggests it will become an increasingly capable partner in the discovery process.
Strengthening data governance and laboratory security
For the lab manager, adopting frontier models requires balancing technical speed with rigorous security and safety oversight. OpenAI is deploying the model through a trusted-access structure for qualified enterprise customers in the US. This framework includes controls around access management, organizational governance, and eligibility. Participating organizations must conduct legitimate scientific research with clear public benefits and agree to strict terms regarding misuse prevention.
Maintaining these safeguards is a critical component for labs that must embed compliance in day-to-day activities to take advantage of AI tools. The model was developed with enterprise-grade security controls to enable professional use in governed research environments. Ongoing partnerships with national laboratories, such as Los Alamos National Laboratory, continue to evaluate the model's impact on protein and catalyst design while ensuring biological structures are modified safely. As the program expands, OpenAI intends to further refine the model’s biological reasoning to support long-horizon research workflows.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.
